Rain Therapeutics Inc. announced the appointment of Richard Bryce, MBChB, as executive vice president and chief medical officer. Dr. Bryce brings over 30 years of experience in oncology, clinical research and biopharmaceutical roles to the Rain team. He joins the company as it prepares to initiate multiple clinical studies for RAIN-32, an oral MDM2 inhibitor, including a Phase 3 clinical trial for patients with well-differentiated/de-differentiated liposarcoma. Dr. Bryce has global biopharmaceutical experience, and joins Rain from Puma Biotechnology, where he served as chief medical and scientific officer since 2017. During his time at Puma from 2012 to 2021, Dr. Bryce led the company’s research and development plans for neratinib, a tyrosine kinase inhibitor, through U.S. Food and Drug Administration approval for the treatment of breast cancer.